Filter Results:
- Full text PDF available (24)
Publication Year
2012
2019
- This year (17)
- Last 5 years (49)
- Last 10 years (57)
Publication Type
Co-author
Journals and Conferences
Learn More
- Dong Lin, Alexander W Wyatt, +22 authors Yuzhuo Wang
- Cancer research
- 2014
Standardized and reproducible preclinical models that recapitulate the dynamics of prostate cancer are urgently needed. We established a bank of transplantable patient-derived prostate cancer… (More)
- Arun A. Azad, Stanislav V. Volik, +15 authors Kim N. Chi
- Clinical cancer research : an official journal of…
- 2015
PURPOSE
Although novel agents targeting the androgen-androgen receptor (AR) axis have altered the treatment paradigm of metastatic castration-resistant prostate cancer (mCRPC), development of… (More)
- Alexander W Wyatt, Arun A. Azad, +13 authors Kim N. Chi
- JAMA oncology
- 2016
Importance
The molecular landscape underpinning response to the androgen receptor (AR) antagonist enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) is undefined.… (More)
- A. V. Lapuk, Chunxiao Wu, +29 authors Colin Collins
- The Journal of pathology
- 2012
The current paradigm of cancer care relies on predictive nomograms which integrate detailed histopathology with clinical data. However, when predictions fail, the consequences for patients are often… (More)
- Matti Annala, Werner J. Struss, +13 authors Alexander W Wyatt
- European urology
- 2017
BACKGROUND
Germline mutations in DNA repair genes were recently reported in 8-12% of patients with metastatic castration-resistant prostate cancer (mCRPC). It is unknown whether these mutations… (More)
- Chunxiao Wu, Alexander W Wyatt, +27 authors Colin Collins
- The Journal of pathology
- 2012
Next-generation sequencing is making sequence-based molecular pathology and personalized oncology viable. We selected an individual initially diagnosed with conventional but aggressive prostate… (More)
- Matti Annala, Gillian Vandekerkhove, +15 authors Kim N. Chi
- Cancer discovery
- 2018
Primary resistance to androgen receptor (AR)-directed therapies in metastatic castration-resistant prostate cancer (mCRPC) is poorly understood. We randomized 202 patients with treatment-naïve mCRPC… (More)
- Jennifer L. Bishop, Daksh Thaper, +16 authors Amina Zoubeidi
- Cancer discovery
- 2017
Mechanisms controlling the emergence of lethal neuroendocrine prostate cancer (NEPC), especially those that are consequences of treatment-induced suppression of the androgen receptor (AR), remain… (More)
- Dong Lin, Hui Xue, +8 authors Yuzhuo Wang
- Asian journal of andrology
- 2014
leading cause of cancer-related death of North American males.1 The disease is at present incurable once it has metastasized, and most deaths from this disease are due to metastases that are highly… (More)
- Gillian Vandekerkhove, Tilman Todenhöfer, +15 authors Alexander W Wyatt
- Clinical cancer research : an official journal of…
- 2017
Purpose: Targeted agents and immunotherapies promise to transform the treatment of metastatic bladder cancer, but therapy selection will depend on practical tumor molecular stratification.… (More)